Navigation Links
CVS Caremark Undertakes Multi-Year Study to Improve Patient Medication Adherence
Date:10/14/2009

WOONSOCKET, R.I., Oct. 14 /PRNewswire/ -- CVS Caremark (NYSE: CVS) is sponsoring research to investigate patient adherence to prescription drug therapies and identify ways to increase adherence. Working with researchers from Harvard and Brigham and Women's Hospital, the company expects knowledge gained from the research will help health professionals better understand patient behavior and lead to developing programs that health care providers and pharmacies can use to improve medication adherence and ultimately help improve patient care and medical outcomes by avoiding costly hospital treatment.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO )

Non-adherence to essential chronic medications has been widely recognized as a major public health problem, according to prior research cited in numerous medical journals. One quarter of original prescriptions for essential medications are never filled, and patients with important chronic diseases such as diabetes and coronary artery disease adhere to their medication only about half of the time. Non-adherence to essential medications is a frequent cause of preventable hospitalizations and patient illness, with costs to the U.S. health care system estimated at over $200 billion annually. A better understanding of the predictors of non-adherence and strategies to improve medication use has the potential to meaningfully impact the public health.

"As the nation looks for ways to reduce health care spending, we need to improve patient compliance with prescribed drug therapies," said Troyen A. Brennan, M.D., Executive Vice President and Chief Medical Officer, CVS Caremark. "Many reasons have been discussed for patient non-adherence, including cost, forgetfulness, confusion when taking mu
'/>"/>

SOURCE CVS Caremark
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CVS Caremark Celebrates Outstanding Pharmacy Care to Patients During American Pharmacists Month in October
2. CVS Caremark Launches Distribution of $3 million in Free Seasonal Flu Shot Vouchers to the Unemployed
3. CVS Caremark Data Confirms Improved Outcomes for Women with Osteoporosis Who are Adherent to Therapy
4. CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year
5. Menicon Undertakes With the Novovision Clinic a Paediatric Myopia Control Clinical Trial
6. The Leukemia & Lymphoma Society and Anjin Group Announce Multi-Year Collaborative Research Agreement
7. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
8. DATATRAK Signs 6 Year Study with New Device Client
9. Study Suggests that NGAL Identifies Acute Kidney Injury Early in ICU Patients
10. Bundling Two Generic Low-Cost Heart Drugs Prevents Heart Attack and Stroke in Large, Diverse Population, Observational Clinical Study Shows
11. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
(Date:6/29/2015)... ... June 29, 2015 , ... Scientists from the Icahn School ... complete genomes by combining high-throughput DNA sequencing with genome mapping. The methodology enabled ... with human disease, but previously difficult to detect. The study was published today ...
(Date:6/29/2015)... Fernando Valley, CA (PRWEB) , ... June 29, 2015 , ... ... non-invasive treatments designed to lift and tighten sagging skin. Ulthera is a special treatment ... surgery. Instead, it uses ultrasound technology to gently stimulate collagen production. Ulthera is highly ...
(Date:6/29/2015)... ... June 29, 2015 , ... The ... Chemical Technology of The Hong Kong Polytechnic University (PolyU) has developed a new ... of edible oils has been a long-term issue in food safety, and becomes ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... company serving the Twin Cities area, provides money-saving tactics during a season of ... Twin Cities’ residents, addressing water conservation and other economical practices. , According to ...
(Date:6/29/2015)... ... , ... BaliniSports has been announced as an official sponsor and apparel provider ... This year’s contestants will be wearing pieces from the BaliniSports collection during practice sessions ... on to represent the state in the Miss Teen USA competition. , “BaliniSports ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:PolyU develops a new method for rapid authentication of edible oils and screening of gutter oils 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 3Health News:BaliniSports Announced as Sponsor of the Miss Teen Nevada 2016 Competition 2
... study, published online in the Journal of Allergy ... therapies against childhood eczema in attempt to reduce the ... conducted by the University of Melbourne, Monash University and ... 8500 people who are part of the Tasmanian Longitudinal ...
... Dental researchers at the University of Washington have reported ... treated with the topical syrup xylitol, a naturally occurring ... General Session of the International Association for Dental Research. ... of the Marshall Islands, children 6 to 15 months ...
... mechanism present early in life predisposes people to worry, ... The brains of people who suffer from anxiety and ... show signs of being anxious even in situations considered ... Wisconsin School of Medicine and Public Health. , ...
... or tooth decay, continues to be the most prevalent ... and socio-economic consequences. It leads to the loss of ... necrosis of the subjacent dental pulp. In the U.S. ... with failure rates of up to 60%. Hence, there ...
... July 4 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: ... of medical devices worldwide, today announced it has ... audited financial statements for,the fiscal year ended December ... (the "SEC") in accordance with United States,requirements. Mindray,s ...
... July 3 The July 5 issue of ... of Istanbul,on Organ Trafficking and Transplant Tourism, an ... May 2, 2008, at an,International Summit of more ... scholars from 78 countries and 20,international organizations. A ...
Cached Medicine News:Health News:Anxiety, Shyness May Be Long-Lasting Traits 2Health News:Novel hydrogel systems for dentin regeneration 2Health News:Mindray Announces 20-F Filing 2Health News:Commentary in The Lancet on the Declaration of Istanbul Sees Organ Transplantation Worldwide Threatened by Organ Trafficking and Transplant Tourism and Commercialism 2
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: